Clinical Trial Update: Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to MDS With del5q, Refractory/Resistant/Intolerant to Prior Treatments, RBC-TD [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating luspatercept for anemia in patients with myelodysplastic syndrome and del(5q) who are refractory to prior treatments and transfusion-de…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome with Del

Drugs mentioned

• REBLOZYL (LUSPATERCEPT)

Snippet

Sponsor: Associazione Qol-one | Conditions: Myelodysplastic Syndromes, Del(5Q) | Phase 2 | Status: RECRUITING